Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The enhanced contractility of the phospholamban-deficient mouse heart persists with aging

Slack, J. P. ; Grupp, I. L. ; Dash, R. ; Holder, D. ; Schmidt, A. LU ; Gerst, M. J. ; Tamura, T. ; Tilgmann, C. LU orcid ; James, P. F. LU orcid and Johnson, R. , et al. (2001) In Journal of Molecular and Cellular Cardiology 33(5). p.1031-1040
Abstract

Phospholamban ablation in the mouse is associated with significant increases in cardiac contractility. To determine whether this hyperdynamic function persists through the aging process, a longitudinal examination of age-matched phospholamban-deficient and wild-type mice was employed. Kaplan-Meier survival curves indicated no significant differences between phospholamban-deficient and wild-type mice over the first year. Examination of cardiac function revealed significant increases in the rates of contraction (+dP/dt) and relaxation (-dP/dt) in phospholamban-deficient hearts compared with their wild-type counterparts at 3, 6, 12, 18 and 24 months of age. Quantitative immunoblotting indicated that the expression levels of the... (More)

Phospholamban ablation in the mouse is associated with significant increases in cardiac contractility. To determine whether this hyperdynamic function persists through the aging process, a longitudinal examination of age-matched phospholamban-deficient and wild-type mice was employed. Kaplan-Meier survival curves indicated no significant differences between phospholamban-deficient and wild-type mice over the first year. Examination of cardiac function revealed significant increases in the rates of contraction (+dP/dt) and relaxation (-dP/dt) in phospholamban-deficient hearts compared with their wild-type counterparts at 3, 6, 12, 18 and 24 months of age. Quantitative immunoblotting indicated that the expression levels of the sarcoplasmic reticulum Ca2+-ATPase were not altered in wild-type hearts, while they were significantly decreased at 12 months (40%) and 18 months (20%) in phospholamban-deficient hearts. These findings on the persistence of hyperdynamic cardiac function over the long terra suggest that phospholamban may constitute an important target for treatment in heart disease.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
keywords
Aging, Contractility, Myocardium, Phospholamban, Sarcoplasmic reticulum
in
Journal of Molecular and Cellular Cardiology
volume
33
issue
5
pages
10 pages
publisher
Elsevier
external identifiers
  • scopus:0034973920
  • pmid:11343424
ISSN
0022-2828
DOI
10.1006/jmcc.2001.1370
language
English
LU publication?
no
id
07f240c2-1540-4dda-81ab-734eccfff671
date added to LUP
2016-04-11 13:05:43
date last changed
2024-02-18 15:57:09
@article{07f240c2-1540-4dda-81ab-734eccfff671,
  abstract     = {{<p>Phospholamban ablation in the mouse is associated with significant increases in cardiac contractility. To determine whether this hyperdynamic function persists through the aging process, a longitudinal examination of age-matched phospholamban-deficient and wild-type mice was employed. Kaplan-Meier survival curves indicated no significant differences between phospholamban-deficient and wild-type mice over the first year. Examination of cardiac function revealed significant increases in the rates of contraction (+dP/dt) and relaxation (-dP/dt) in phospholamban-deficient hearts compared with their wild-type counterparts at 3, 6, 12, 18 and 24 months of age. Quantitative immunoblotting indicated that the expression levels of the sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase were not altered in wild-type hearts, while they were significantly decreased at 12 months (40%) and 18 months (20%) in phospholamban-deficient hearts. These findings on the persistence of hyperdynamic cardiac function over the long terra suggest that phospholamban may constitute an important target for treatment in heart disease.</p>}},
  author       = {{Slack, J. P. and Grupp, I. L. and Dash, R. and Holder, D. and Schmidt, A. and Gerst, M. J. and Tamura, T. and Tilgmann, C. and James, P. F. and Johnson, R. and Gerdes, A. M. and Kranias, E. G.}},
  issn         = {{0022-2828}},
  keywords     = {{Aging; Contractility; Myocardium; Phospholamban; Sarcoplasmic reticulum}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{1031--1040}},
  publisher    = {{Elsevier}},
  series       = {{Journal of Molecular and Cellular Cardiology}},
  title        = {{The enhanced contractility of the phospholamban-deficient mouse heart persists with aging}},
  url          = {{http://dx.doi.org/10.1006/jmcc.2001.1370}},
  doi          = {{10.1006/jmcc.2001.1370}},
  volume       = {{33}},
  year         = {{2001}},
}